Reuters logo
FDA approves Boehringer-Lilly drug for type-2 diabetes patients
February 2, 2015 / 2:01 PM / 3 years ago

FDA approves Boehringer-Lilly drug for type-2 diabetes patients

(Reuters) - The U.S. Food and Drug Administration approved a drug developed by Eli Lilly and Co and privately held Boehringer Ingelheim Pharmaceuticals Inc to improve blood sugar control in type-2 diabetes patients, the companies said.

The drug, Glyxambi, combines empagliflozin and linagliptin, commonly prescribed diabetes medications which are manufactured by Lilly and Boehringer.

Reporting by Amrutha Penumudi in Bengaluru; Editing by Don Sebastian

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below